These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 17075867)

  • 21. Grapefruit juice--drug interactions: importance for pharmacotherapy.
    Cuciureanu M; Vlase L; Muntean D; Varlan I; Cuciureanu R
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(3):885-91. PubMed ID: 21235125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
    HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of a conscious rat model for the discovery of novel agents that inhibit gastric acid secretion.
    Campbell CA; Gaskin PJ; Darton J; Chiu P; Lee K; McLean PG
    Eur J Pharmacol; 2008 Jul; 589(1-3):260-3. PubMed ID: 18571645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using pharmacokinetic modeling to determine the effect of drug and food on gastrointestinal transit in dogs.
    Sjödin L; Visser S; Al-Saffar A
    J Pharmacol Toxicol Methods; 2011; 64(1):42-52. PubMed ID: 21596146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the guinea pig monophasic action potential (MAP) assay in predicting drug-induced delay of ventricular repolarisation using 12 clinically documented drugs.
    Kågström J; Sjögren EL; Ericson AC
    J Pharmacol Toxicol Methods; 2007; 56(2):186-93. PubMed ID: 17582787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
    Klein CE; Chiu YL; Cai Y; Beck K; King KR; Causemaker SJ; Doan T; Esslinger HU; Podsadecki TJ; Hanna GJ
    J Clin Pharmacol; 2008 May; 48(5):553-62. PubMed ID: 18440920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of salbutamol and propranolol on pentagastrin, histamine and meal-stimulated acid and pepsin secretion in the dog.
    McCloy RF; Dawson VA; Baron JH
    Acta Hepatogastroenterol (Stuttg); 1979 Oct; 26(5):399-406. PubMed ID: 393041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
    Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.
    Zhu L; Persson A; Mahnke L; Eley T; Li T; Xu X; Agarwala S; Dragone J; Bertz R
    J Clin Pharmacol; 2011 Mar; 51(3):368-77. PubMed ID: 20457590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances and challenges in PBPK modeling--Analysis of factors contributing to the oral absorption of atazanavir, a poorly soluble weak base.
    Berlin M; Ruff A; Kesisoglou F; Xu W; Wang MH; Dressman JB
    Eur J Pharm Biopharm; 2015 Jun; 93():267-80. PubMed ID: 25872159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro evaluation of food effect on the bioavailability of rifampicin from antituberculosis fixed dose combination formulations.
    Panchagnula R; Rungta S; Sancheti P; Agrawal S; Kaul CL
    Farmaco; 2003 Nov; 58(11):1099-103. PubMed ID: 14572860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of food on the oral bioavailability of deramciclane from film-coated tablet in healthy male volunteers.
    Drabant S; Nemes KB; Horváth V; Tolokán A; Grézal G; Anttila M; Gachályi B; Kanerva H; Al-Behaisi S; Horvai G; Klebovich I
    Eur J Pharm Biopharm; 2004 Nov; 58(3):689-95. PubMed ID: 15451546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of food on the pharmacokinetics of a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240.
    Cirillo I; Martin NE; Brennan B; Barrett JS
    J Clin Pharmacol; 2004 Dec; 44(12):1379-84. PubMed ID: 15545308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An unusual case of HIV virologic failure during treatment with boosted atazanavir.
    Duncan A; Mills J
    AIDS; 2013 May; 27(8):1361-2. PubMed ID: 23925384
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
    McRae M; Clay PG; Anderson PL; Glaros AG
    Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.
    Hulskotte EG; Feng HP; Xuan F; van Zutven MG; Treitel MA; Hughes EA; O'Mara E; Youngberg SP; Wagner JA; Butterton JR
    Clin Infect Dis; 2013 Mar; 56(5):718-26. PubMed ID: 23155151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using Agenerase. Nutritional considerations affect bioavailability of new P.I.
    Tong C; Fenton M; Hall M
    Posit Living; 1999 Jul; 8(6):6, 62. PubMed ID: 12492049
    [No Abstract]   [Full Text] [Related]  

  • 40. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
    J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.